We’re excited to announce that Mtech Access is now Powered by PetauriTM

A purpose-built pharmaceutical-services platform, Petauri is actively partnering with best-in-class companies recognised for their expertise in global market access, health systems, medical affairs, HEOR, patient services, and data and analytics.

As part of Petauri, Mtech Access will offer broader expertise to seamlessly support our valued clients with impactful solutions that speed patient access to life-changing care. Find more details here.

Strategic partners for key market access milestones

We partner with market access and HEOR teams across all global and local milestones, providing the strategy, insight, evidence, and materials to ensure commercial success.

Phase 2

Is there a market for this product? Is there likely to be a return on investment of clinical trials? What is the reimbursement potential?

Recommended approach:

  • Opportunity assessment
  • Competitor landscape analysis
  • Payer landscape analysis
  • Price and reimbursement potential analysis
  • Early health economic evaluation and modelling

Outcome: Decision-making and the foundations of future market access supported by evidence and strategic insight.

Phase 2-3

What is the strategy to take this product to market? Where and how can we launch? What is our global pricing and reimbursement strategy?

Recommended approach:

  • Market analysis (including competitor landscape analysis, insights from analogous products, and analysis of prior health technology assessment (HTA) or reimbursement decisions)
  • Target product profile testing
  • Price benchmarking and testing
  • Market access strategy development
  • Evidence generation plan development
  • Competitor defence strategy

Outcome: A comprehensive strategy for global market access that is driven by market, competitor, and payer insights.

Phase 3 to launch

Do we have the value messaging and evidence to secure reimbursement in key markets?

Recommended approach:

  • Value proposition development (with payer validation)
  • Evidence synthesis via systematic literature review, network meta-analysis, and/or indirect treatment comparisons
  • Health economic models (e.g. cost-effectiveness model and budget impact model)
  • Value dossier and objection handler
  • Hosting of materials on global value platform
  • Publication strategy and development
  • Roll out of global value materials to local affiliates and support with local adaptation for key markets

Outcome: Impactful messaging, value materials, and evidence ready for local affiliates launches.

Phase 3 to launch and beyond

How do we secure HTA recommendations across the UK and Ireland?

Recommended approach:

  • Evidence review and gap analysis, review or development of health technology assessment (HTA) strategy
  • Starting in England: National Institute for Health and Care Excellence (NICE) HTA submission – full HTA support, including systematic literature reviews (clinical and economic), cost-effectiveness models (CIMs) and budget impact models (BIMs), advisory boards, expert elicitation, submission dossiers, and post-NICE submission services, such as mock meetings and scenario analysis
  • Moving to Scotland: Scottish Medicines Consortium (SMC) submission – adaptation of NICE submission to meet SMC requirements (e.g. update of CEMs and BIMs) and incorporation of key learns from NICE submission and any newly published evidence
  • Then to Ireland: National Centre for Pharmacoeconomics (NCPE) submission adaptation of NICE/SMC dossiers to meet NCPE requirements (e.g. update of BIMs) and key learns
  • Commercial launch plan review – sharing learnings from HTA process for local market access teams

Outcome: Robust HTA strategies and submissions to secure approval in these key markets.

How do we launch this product in the key local market? What do we need to engage local payers?

Recommended approach:

  • Development of launch strategy
  • Review and analysis of global value materials and re-development for local market
  • Ad board with local key opinion leaders
  • Above-brand ‘case for change’ messaging
  • Localised value propositions/narrative
  • Localised economic modelling (e.g. budget impact model)
  • Leave pieces/guidelines influencing pieces
  • Price negotiation strategy and training
  • Objection handling
  • User guides for materials

Outcome: Comprehensive local market access strategy and engagement tools to support field team communication with local payers.

How do we navigate the UK healthcare system? What do we need to engage NHS decision-makers and drive change?

Recommended approach:

Recommended approach for launching in key local markets, plus…

  • Service assessment and re-design support
  • Advanced notifications/advanced budgetary planning
  • Workshops on understanding the NHS environment
  • Costed patient pathways
  • Pre-launch field team training
  • NHS stakeholder mapping
  • Support and training on how to engage with different operational, strategic, and clinical stakeholders across the NHS
  • Specific support for key NHS policies, e.g. specialised commissioning

Outcome: Strategy and insights needed to successfully engage NHS decision-makers and drive change.

We provide strategy and solutions to help Pharma and Medtech companies bring interventions to market, providing more patient choice and meeting the needs of the healthcare environment.

Our consultants and technical experts support global teams and affiliates throughout the product life cycle, from evidence generation and strategy to communication of value.

We support international market access teams in these key launch markets

United Kingdom Flag

United Kingdom

Germany

Germany

France

France

Italy

Spain

Spain

Canada

Canada

United States

USA

Australia

Australia

China

China

Japan

Japan

CASE STUDY

Delivering on global market access strategy, evidence generation and communication objectives

Our client’s global market access team were looking for a consultancy who could support them from strategy to implementation. As the client was in the early stages of developing a new product, they first wanted to understand the challenges and opportunities that their new treatment would face when launching in different markets.

Get in touch

Honestly, the best agency i have ever worked with. It felt like we were working with a partner not an agency!
View our client testimonials

Download a PDF brochure and share the Mtech Access story with colleagues

Download our Mtech Access Brochures

To discuss your requirements with our experts, get in touch using the form below.

    Keep me up to date with the latest news and events.

    Latest news

    At Mtech Access we are always striving to engage with the wider market access community and share our thoughts on the latest industry issues or methods development.

    Keep up-to-date with our latest insights by following us on

    Mtech Access on Linkedin

    Twitter

    YouTube

    Podcast

    NHS Whispers on LinkedIn

    Subscribe to our newsletter